Who Exports Bambuterol from India — 4 Suppliers Behind a $141.2K Market
India's bambuterol export market is supplied by 4 active exporters who collectively shipped $141.2K across 12 shipments. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 51.4% market share. The top 5 suppliers together control 51.4% of total export value, reflecting a moderately competitive market structure.
Top Bambuterol Exporters from India — Ranked by Export Value
SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading bambuterol exporter from India, holding a 51.4% share of the $141.2K market across 12 shipments from 4 exporters. The top 5 suppliers — SUN PHARMACEUTICAL INDUSTRIES LIMITED — collectively control 51.4% of total export value, indicating a moderately concentrated market. Individual shares are: SUN PHARMACEUTICAL INDUSTRIES LIMITED (51.4%).
Top Bambuterol Exporters from India
Ranked by export value · 4 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED BETADAY 10 TABLETS (BAMBUTEROL HYDROCHLOBETADAY 10 TABLETS PACK: 10*10 BATCH: JME0765A | $72.6K | 1 | 51.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Bambuterol exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Warning Letter issued in | Yes | Yes | Not verified | Received FDA Warning Letter for Dadra facility in June 2024; holds WHO-GMP and E |
TransData Nexus reviewed the regulatory standing of 1 leading Bambuterol exporters from India. 0 hold US FDA facility approvals, 1 maintain WHO-GMP certification, and 1 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Bambuterol sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. The city is renowned for its production of active pharmaceutical ingredients (APIs), vaccines, and biologics. The presence of Genome Valley, India's first biotech cluster, underscores Hyderabad's significance in pharmaceutical manufacturing and research.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a pivotal formulations hub, contributing nearly 28% of India's pharmaceutical production. This region is home to industry leaders such as Zydus Lifesciences and Cadila Pharmaceuticals. The area's robust infrastructure, including multiple Special Economic Zones (SEZs), supports a diverse range of pharmaceutical activities, from APIs to finished formulations and biopharmaceuticals.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. This region houses the headquarters of major companies like Sun Pharma and Cipla, facilitating corporate functions, regulatory affairs, and R&D. Its strategic location and well-developed infrastructure make it a central hub for pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as Asia's largest pharmaceutical manufacturing hub, hosting over 1,000 pharma companies. The region's growth is driven by favorable government policies, including tax incentives and excise duty exemptions, making it a cost-effective destination for pharmaceutical manufacturing.
5Sourcing Recommendations
- Diversify Supplier Base: While Sun Pharmaceutical Industries Limited is a major supplier, consider engaging with other manufacturers in regions like Hyderabad and Ahmedabad to mitigate supply chain risks.
- Leverage Tax Incentives: Explore partnerships with manufacturers in Baddi-Nalagarh to benefit from tax incentives and cost-effective production.
- Assess Export Logistics: Utilize the Mumbai-Thane-Raigad region's infrastructure for efficient export operations, ensuring timely delivery to key markets like Myanmar and Afghanistan.
- Monitor Regulatory Compliance: Ensure all suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Bambuterol exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma Completes Taro Merger
Sun Pharma completed the merger with Taro Pharmaceutical Industries Ltd., acquiring all outstanding ordinary shares not already held by Sun Pharma or its affiliates. This consolidation aims to enhance competitiveness in the generics industry. IMPACT: The merger may bolster Sun Pharma's manufacturing and distribution capabilities, potentially affecting Bambuterol export volumes.
Impact: The merger may bolster Sun Pharma's manufacturing and distribution capabilities, potentially affecting Bambuterol export volumes.
Sun Pharmaceutical Industries Limited — Sun Pharma Invests $15 Million in Pharmazz
Sun Pharma entered into an agreement with Pharmazz, Inc., investing up to $15 million to support the Phase 3 study of Sovateltide for acute cerebral ischemic stroke. The agreement also expands Sun Pharma's exclusive license for Sovateltide to additional emerging markets. IMPACT: This investment may lead to resource reallocation, potentially influencing the focus on Bambuterol exports.
Impact: This investment may lead to resource reallocation, potentially influencing the focus on Bambuterol exports.
Sun Pharmaceutical Industries Limited — Sun Pharma Completes Acquisition of Concert Pharmaceuticals
Sun Pharma acquired Concert Pharmaceuticals, adding Deuruxolitinib, a potential best-in-class oral JAK inhibitor for alopecia areata, to its global dermatology portfolio. IMPACT: The acquisition may diversify Sun Pharma's product offerings, potentially affecting the strategic emphasis on Bambuterol exports.
Impact: The acquisition may diversify Sun Pharma's product offerings, potentially affecting the strategic emphasis on Bambuterol exports.
Common Questions — Bambuterol Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which bambuterol supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 8 recorded shipments worth $72.6K. (0 shipments) and (0 shipments) are also established high-volume exporters.
Q How many bambuterol manufacturers are there in India?
India has 4 active bambuterol exporters with a combined export market of $141.2K across 12 shipments to 2 countries. The top 5 suppliers hold 51.4% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for bambuterol from India?
Average FOB unit price: $6.91 per unit, ranging from $0.20 to $8.28. Average shipment value: $11.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 4 verified Indian exporters of Bambuterol ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 12 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 2 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
12 Verified Shipments
4 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists